首页> 外文期刊>Physiological Reports >Oral and intravenous pharmacokinetics of taurine in sprague?¢????dawley rats: the influence of dose and the possible involvement of the proton?¢????coupled amino acid transporter, PAT1, in oral taurine absorption
【24h】

Oral and intravenous pharmacokinetics of taurine in sprague?¢????dawley rats: the influence of dose and the possible involvement of the proton?¢????coupled amino acid transporter, PAT1, in oral taurine absorption

机译:牛磺酸在大鼠体内的口服和静脉药代动力学:剂量的影响以及质子偶联氨基酸转运蛋白PAT1可能参与口服牛磺酸的吸收

获取原文
       

摘要

Taurine is involved in various physiological processes, and one of the most abundant amino acids in human. The aim was to investigate the mechanism for intestinal absorption of taurine in????vivo using also in????vitro mechanistic studies. Taurine absorption was measured in male Sprague?¢????Dawley rats at 10?¢????997????mg/kg and 1?¢????30????mg/kg for oral and intravenous administration, respectively. Oral absorption was measured in the presence of substrates for the proton?¢????coupled amino acid transporter, PAT1, that is, 200????mg/kg proline (Pro) and sarcosine (Sar), and in the presence of 2?¢????Amino?¢????2?¢????norbornanecarboxylic acid (BCH) (200????mg/kg). BCH is not an inhibitor of PAT1 or the taurine transporter, TauT, hence it was included as a negative control. In vitro studies investigating the transport mechanism of taurine were conducted in human intestinal Caco?¢????2 cells. The pharmacokinetic investigations showed that intestinal taurine absorption was not saturable at the investigated doses, but that the time ( t max ) to reach the maximal plasma concentration ( C max ) increased with dose. Furthermore, Sar and Pro, but not BCH, decreased taurine C max . In vitro it was clearly shown that PAT1 mediated the cellular uptake of taurine and thereby facilitated the transepithelial taurine transport, which could be inhibited by Pro and Sar, but not BCH. In vivo and in????vitro results suggest that taurine absorption from the intestine is caused by PAT1.
机译:牛磺酸参与各种生理过程,是人体内最丰富的氨基酸之一。目的是利用体外机理研究来研究牛磺酸在体内肠道吸收的机理。在雄性Sprague Dawley大鼠中,牛磺酸的吸收测定为10 9毫克/千克和997毫克/千克,口服和口服30毫克/千克。分别静脉注射。在存在质子偶联的氨基酸转运蛋白PAT1的底物存在下,即200mg / kg的脯氨酸(Pro)和肌氨酸(Sar),并在存在下测量口服吸收。的2A氨基氨基2烷2(2)降冰片烷羧酸(BCH)(200 ??? mg / kg)。 BCH不是PAT1或牛磺酸转运蛋白TauT的抑制剂,因此被作为阴性对照。在人肠中的Cacoβ2细胞中进行了研究牛磺酸转运机制的体外研究。药代动力学研究表明,在所研究的剂量下肠牛磺酸吸收不饱和,但是达到最大血浆浓度(C max)的时间(t max)随剂量增加。此外,Sar和Pro(而非BCH)降低了牛磺酸C max。在体外,清楚地表明,PAT1介导牛磺酸对细胞的摄取,从而促进了上皮牛磺酸的转运,而Pro和Sar可以抑制牛磺酸的转运,但BCH不能。体内和体外结果表明,牛磺酸从肠道的吸收是由PAT1引起的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号